KA
KERX

Kovack Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Kovack Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,600
Closed -$52K – 555
2018
Q1 		$52K Buy
12,600
+1,000
+9% +$4.66K 0.01% 473
2017
Q4 		$54K Buy
+11,600
New +$63.9K 0.01% 446

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kovack Advisors's KERX Position: Q2 2018 in Review

Kovack Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2018, closing a stake of 12,600 shares — an estimated $52K sold.

Kovack Advisors first reported a position in KERX in Q4 2017 and held it in 2 quarters. The position peaked at $54K in Q4 2017. 132 funds tracked by Wall St. Rank hold KERX as of Q2 2018.

  • Kovack Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • Kovack Advisors sold 12,600 Keryx Biopharmaceuticals Inc shares in Q2 2018, an estimated $52K.
  • Kovack Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q4 2017 and held it in 2 quarters.
  • Kovack Advisors's Keryx Biopharmaceuticals Inc position peaked at $54K in Q4 2017.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2018.

Based on Kovack Advisors's 13F filing for Q2 2018, filed 1 Aug 2018.